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Introduction
Diet is an important lifestyle exposure and is the largest modifiable 
determinant of risk for non-communicable disease, including car-
diovascular disease, diabetes and some cancers. Importantly, diet 
is an ongoing, essential and unavoidable exposure for all people 
throughout life. Worldwide, non-communicable diseases account 
for 43% of the burden of disease currently, and the World Health 
Organization predicts they will represent 60% of the disease bur-
den and 73% of all deaths by 2020.1 The number of people with 
diabetes worldwide rose to 422 million in 2014,2 cardiovascular 
disease is the leading cause of death,3 and incidence of cancers re-
lated to dietary risk factors, such as colorectal and esophageal can-
cers, are also rising.4 Today, most of the world’s population lives 
in a country where overweight and obesity kills more people than 
underweight.5 Diet is, therefore, considered as a primary preven-
tion strategy to reduce the risk for chronic diseases. However, as 
highlighted by the “Rose prevention paradox”, a lifestyle measure 
that reduces risk in an entire population may offer little benefit to 
the individual.6
Current public health initiatives and nutritional guidelines, both 
on a global and national scale, are generic recommendations. These 
recommendations are based on population estimates of required in-
takes and the prevention of deficiency.7 However, it is well known 
that there is considerable variance in how individuals respond to 
the same nutritional stimuli, and this alters the outcomes in terms 
of benefits and risks. The broader concept of personalized nutrition 
is not new, and population guidelines recognize some of this vari-
ance in limited cases, with some recommendations tailored to age, 
sex, or conditions such as pregnancy.8 Ranges of recommended in-
take values also account for a portion of this biological variance, as 
do specific recommendations related to the diagnosis of particular 
conditions, such as allergies or chronic diseases such as diabetes,9 
cardiovascular disease and cancers.10,11
However, population guidelines, even with stratification, may 
not meet the needs of all individuals equally in terms of optimizing 
health outcomes and reduction of disease risk.12,13 With improv-
ing technology and advances in our understanding of genetics, the 
concept of personalized nutrition via nutrigenetics has emerged, 
where dietary recommendations can take into account the variance 
between individuals by tailoring to each person’s unique genet-
ics.13–15 While personalized nutrition based on genetics has sig-
nificant future promise, there are many challenges in translating 
scientific advances into successful strategies for managing dietary 
intake and diet-related health outcomes on a large scale. These is-
sues include the translation of reductionist research outcomes into 
practice, public perception and the likelihood of uptake, issues of 
privacy and ethics, commercialization, and the level of evidence 
required before the transition from traditional approaches is ben-
eficial. It is important to consider if these challenges can be met 
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and whether personalized nutrition can produce improved health 
outcomes and socioeconomic benefits relative to conventional ge-
neric dietary advice.
Gene-nutrient interactions
Dietary factors can interact with the genome in a number of ways. 
Firstly, genetic variance can influence nutritional status by modu-
lating nutrient intake, uptake and metabolism. This is referred to as 
nutrigenetics.16 Furthermore, nutrients can regulate gene expres-
sion in a number of ways. Some nutrients can directly regulate 
gene expression via the interaction of stimulated receptors with 
response elements in the genome, acting as nuclear transcription 
factors. This direct interaction is referred to as nutrigenomics.16 
Nutrients can also modify gene expression indirectly, via modula-
tion of gene regulatory factors such as epigenetic marks, including 
the involvement of DNA methylation and miRNA.17 Importantly, 
nutrigenetics can impact upon the nutrigenomic and epigenetic 
responses and the sum of these events can modify disease risk.18
With improving technology, and completion of ground-breaking 
research, such as the human genome project, we are learning more 
about gene-nutrient interactions. This has led to a dramatic increase 
in research in this area. However, there are significant challenges to 
the translation of genetic data into personalized dietary advice, and 
it is questionable as to whether our level of understanding is suf-
ficient for personalized nutrigenetics to progress. The majority of 
the published data on gene-nutrient interactions stem from observa-
tional studies and as such cannot definitively demonstrate cause and 
effect, and results can often be conflicting. Purpose-specific dietary 
intervention studies conducted by genotype are needed to achieve 
this. However, these are complex and expensive, and there are dif-
ficulties in considering multiple polymorphisms. Numerous genetic 
variants that influence nutrient metabolism have been identified, 
but it can be difficult to conclusively link single variants to the risk 
for multifactorial diseases, due to interactive and additive effects of 
multiple variants in defining nutrient metabolism and health out-
comes. There is a need for quantitative assessment and mathemati-
cal modelling of multiple genetic effects.
Ultimately, the most important question is whether nutrigenet-
ics can deliver results superior to population recommendations. It 
has been argued that the evidence for nutrigenetics is still too im-
mature to be used in practice.19,20 However, it has also been argued 
that nutrigenetics is often held to a higher standard of evidence 
than generic nutritional advice,21,22 resulting in high-quality evi-
dence for several gene-diet interactions potentially being ignored. 
Given the complexity of gene-nutrient interactions, and the known 
variance in nutrition-related health outcomes, regardless of genet-
ics, we need to consider if we have set this standard too high. Nu-
trition is complex and outcomes difficult to assess, with or without 
a genetic component. It is, therefore, necessary to consider person-
alized nutrition in the same context as generic nutrition recommen-
dations and not in the same context as clinical genetics.23
Nutrigenetic research often takes a reductionist approach to 
gene-nutrient interactions, examining the interactions between 
single polymorphisms and individual disease biomarkers, and 
how they are modified by single nutrients or food components.23,24 
Each individual possesses potentially hundreds of gene variants 
that may have nutrigenetic consequences, and each consumes their 
own unique complex and varied diet. Complex statistical and bio-
informatics modelling is required to integrate information on nu-
merous genes, biomarkers, nutrients and foods for nutrigenetics to 
deliver on its promise of improving health outcomes.
An early application of nutrigenetics has been the diagnosis of 
conditions caused by single polymorphisms, such as genetic lac-
tose intolerance and phenylketonuria.25 In many cases, genetic 
testing is not required for monogenic conditions, as the phenotype 
is sufficient basis for deciding on the appropriate dietary interven-
tion. However, for complex polygenic traits, such as cardiovas-
cular disease or diabetes, it is much more challenging to find evi-
dence for the involvement of genes in disease development. These 
conditions have genetic risk factors, dietary risk factors, and these 
risks are modified by the interaction between the two and other 
lifestyle factors.26,27 As such, it is difficult to elucidate the involve-
ment and modifiable component of the interactive factors, and a 
medical model of nutrigenetics, held to a clinical genetics level of 
evidence, may not be appropriate.
Cardiovascular disease
Cardiovascular disease has both genetic and dietary risk factors, 
and risk is likely modified by the interactions between the two.28 
The predictive value of single polymorphisms may be small rela-
tive to known risk factors, such as family history of cardiovascular 
disease.29 Multiple minor genetic differences could be modulated 
by multiple dietary factors, resulting in multiple minor changes 
in gene expression. Depending on the interactions, these variables 
could result in negligible changes in final phenotype and therefore 
disease risk; however, they could also accumulate to significantly 
alter phenotype and outcomes. We do not yet have enough evi-
dence to elucidate the mechanisms and outcomes of these complex 
interactions, and it is likely that additional interactions remain 
undiscovered.30 In the future, advances in this understanding may 
be supported by increased research investment in whole genome 
sequencing and bioinformatics initiatives, as well as improving 
technology and reducing associated testing costs.
Homocysteine is accepted as an independent risk factor for car-
diovascular disease,31 with homocysteine levels being inversely as-
sociated with folate levels. It has been established that the MTH-
FR-677T allele results in the enzyme methylenetetrahydrofolate 
reductase having reduced activity (~35% of the MTHFR-677C 
variant).32 Low folate status, therefore, impacts homocysteine levels 
more severely in individuals with the MTHFR-677TT genotype, and 
the standard recommendations for folate intake have been shown to 
be insufficient to maintain homocysteine levels below the risk level 
in this population. It is accepted that increasing folate intake (from 
200 µg/day to 400–600 µg/day) reduces the risk for hyperhomo-
cysteinemia in most MTHFR-677TT individuals. There is no reli-
able evidence that these levels cause harm, and they remain below 
the upper intake limits found in generic advice.33 As such, this is 
an example of where personalized recommendations may result in 
improved outcomes. However, this could also support the increase 
in population-wide intakes, as homocysteine levels are reduced in 
populations exposed to folic acid fortification programs.34–37
The response of plasma low-density lipoprotein and triacylg-
lycerols (triglycerides) to supplementation with fish oil are clear 
examples of individual variability in response to an intervention 
resulting from the influence of both genetic and environmental fac-
tors. In a study of fish oil supplementation in 55 males, the mean 
change in plasma triacylglycerol was a 35% reduction. However, 
the variance of individual changes ranged from a 114% reduction 
to an 88% increase, demonstrating that the statistically significant 
reduction in the mean did not result in an improved outcome for 
all individuals. Similarly, the mean change for plasma low-density 
lipoprotein was a 7% increase, but with the variance of change 
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ranging from a 61% increase to a 50% reduction.38,39 In the same 
cohort,38 and independently,40 it was determined that the APOE2 
genotype was related to the magnitude of response, and this re-
sponse may also be related to sex.41
Together these data suggest that while fish oil supplementation 
may improve cardiovascular biomarkers for a subset of individu-
als this is not true for all, and in some cases, it may actually be 
detrimental. As such, this may be an example of where it is not ap-
propriate to produce population-based recommendations, whether 
they are public health guidelines, or used for the marketing of sup-
plements. However, there is a lack of evidence to link the variance 
in responses to genotype,42 and further prospective studies includ-
ing genotyping are needed to understand how personalized recom-
mendations could be used to overcome the variance in responses 
and to assess whether this ultimately impacts disease risk, as these 
interactions remain poorly understood.
Diabetes
It is known that type 2 diabetes has both dietary and genetic risk 
factors and that outcomes are dependent on the combined and/or 
interactive influence of these, and other lifestyle risk factors.43–45 
The majority of genes implemented in the progression of type 2 
diabetes relate to pathways influencing fat distribution and insulin 
sensitivity. Genetic risk scores for type 2 diabetes are robust pre-
dictors of disease and have been shown to interact with western 
diets (high fat and sugar) to further predict outcomes.46
Genome-wide association studies (GWAS) have identified 
nearly 100 gene variants associated with modified risk for type 
2 diabetes,47 with a recent review suggesting 27 of these inter-
act with diet to modify progression of type 2 diabetes.48 Notably, 
the transcription factor 7-like 2 gene (TCF7L2), involved in Wnt 
signaling, has the strongest influence on risk for type 2 diabetes. 
Common variants in this gene have been shown to interact with 
high intake of both carbohydrate and fiber to modify risk for type 
2 diabetes.49,50 Due to the direct association between obesity and 
type 2 diabetes risk, a number of gene-diet interactions modifying 
risk of obesity have been identified that are of relevance to type 
2 diabetes. Examples include the interactions between genotypes 
for the fat mass and obesity associated gene (FTO),51 PPARG,52,53 
PLIN,54 and MC4R and diet,55 which influence disease-related out-
comes, such as insulin sensitivity.
GWAS has also identified more than 40 independent polymor-
phisms associated with type 1 diabetes; however, the loci identi-
fied do not fully explain the heritability component estimated from 
familial studies,56 suggesting that dietary and other lifestyle factors 
are also involved in pathogenesis. Additional studies are needed to 
fully elucidate the role of gene-nutrient interactions in the etiology 
of diabetes.
Cancer
A plethora of genes have been linked to cancer risk and outcomes. 
However, few associations between gene variants and cancer risk 
remain robust, or reproducible, likely due to the interactive influ-
ence of diet and other environmental factors in epidemiological 
studies.57 Genome instability is a hallmark feature of cancers, with 
hundreds of genes involved in maintaining genome integrity.58 
The interactions between these genes and diet indicate potential 
mechanisms by which personalized nutrition may influence cancer 
outcomes.59
Gene variants involved in gene-diet interactions in cancer are 
namely those involved in detoxifying carcinogens and repairing 
DNA damage. The majority of these are specific to colorectal can-
cer, which has clear links to dietary risk factors.60,61 Increased risk 
of colorectal cancer has been shown with high red meat consump-
tion in combination with variants in CYP2E1, CYP1B1, SULT1A1 
and other members of the cytochrome P450 family of detoxifying 
genes.62–64 Several other gene variants have also been implicated 
in gene-diet interactions that have been shown to decrease colo-
rectal cancer risk. Notably, common variants in the vitamin D re-
ceptor gene and MTHFR which codes for an important enzyme 
in folate metabolism; both have been shown to decrease risk of 
colorectal cancer when combined with diets high in calcium/vita-
min D and folate respectively.65–67 Whilst the majority of reported 
gene-diet interactions are specific to colorectal cancers, gene-diet 
interactions have also been reported in progression of gastrointes-
tinal, stomach, breast, lung and prostate cancer.57
Another well-studied gene-nutrient interaction involves cruci-
ferous vegetables, which have been linked by systematic review 
with reduced lung cancer in individuals with polymorphisms in 
the GSTT1 and GSTM1 genes, which code for glutathione s-trans-
ferases, but not in individuals without these variants.68,69 However, 
it is unclear how clinically relevant these findings will prove to be, 
as the standard public health message to eat less meat and more 
vegetables applies regardless of genotype and is likely to be in-
volved in the reduction of risk of multiple diseases. The benefit 
of these findings, however, may be found in the development of 
nutraceuticals for intervention in genetically at-risk individuals, 
should a mechanism for this interaction be identified. Interac-
tions have also been shown between genes and diet in measures of 
DNA damage,70 prostate cancer risk and levels of the glutathione 
s-transferase alpha.71,72
Cognitive decline
APOE has been identified as a susceptibility gene for Alzheimer’s 
disease, with the e4 variant increasing risk for disease. The Risk 
Evaluation and Education for Alzheimer’s Disease (commonly 
known as REVEAL) study examined how knowing APOE e4 sta-
tus impacted behavior change in the adult offspring of parents with 
Alzheimer’s disease.73 Having a parent who suffered from the dis-
ease, all study participants showed a higher-than-average risk for 
Alzheimer’s disease, regardless of genotype; however, those car-
rying the APOE e4 variant were at higher risk. Participants were 
given a numerical estimate of their risk and were then randomly 
allocated into groups. Controls were not given any genotypic data, 
and the intervention groups were genotyped for APOE e4 and their 
status revealed to them. Participants who were APOE e4-positive 
had a higher overall numerical risk score.73,74 One year later, simi-
lar proportions of positive behavior changes were reported among 
controls and among participants who were told that they were 
APOE e4-negative; however, additional positive behavior changes 
were reported approximately twice as often among participants 
who were told that they had the APOE e4 risk variant.73
Obesity
Obesity is related to both dietary and genetic variables, and again 
the interaction between the two are likely to be important in deter-
mining phenotype, both in terms of risk for obesity and risk for dis-
eases where obesity is a known risk factor.75 GWAS has revealed 
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that body fat patterns have large genetic components, with 97 loci 
related to fat accumulation and an additional 49 loci relating to 
body fat distribution.76,77 Implicated genes in these loci have di-
verse roles and are involved in pathways such as those regulating 
satiety, food intake, energy metabolism and adipogenesis.76 Mo-
nozygotic (i.e. identical) twins have strong similarities in the adap-
tation to long-term overfeeding and in terms of weight gain and fat 
distribution,78 demonstrating genetic concordance.
Insight into genes that influence obesity has led to the calcula-
tion of genetic risk scores, the sum of obesity risk conferred by 
multiple gene variants. Diet (particularly fat and energy intake) 
has been shown to interact with genetic risk scores to alter the obe-
sity risk.79 Genes implemented in diet-gene interactions in obesity 
namely include FTO, MC4R, APOA2, PLIN and PPARG genes. 
FTO is regarded as the first identified obesity gene. Common ge-
netic variance in FTO is strongly associated with increases in body 
mass index, with this association shown to be enhanced by diets 
high in dietary fat and protein.80,81 Similar associations have been 
found for the MC4R gene, involved in appetite regulation.82,83
Gene-diet interactions in obesity have also been shown between 
high saturated fat intake and APOA2, which codes for an apolipo-
protein,84 and variants in PPARG, which codes for a nuclear tran-
scription factor.52,85 Notably, a common polymorphism in PLIN, 
which is involved in the regulation of lipid storage in adipocytes, 
has been shown to decrease risk of obesity when combined with 
a high carbohydrate intake, but increases obesity risk when com-
bined with a low intake of this macronutrient.86 These data dem-
onstrate the difficulty in the “one-size fits all” approach to weight 
management, and in particular, weight loss.
In a study conducted on patients with a history of weight loss 
failures, it was found that nutrigenetic screening resulted in in-
creased compliance and longer-term body mass index reductions, 
when compared with standard weight-loss advice.87 However, it 
was also shown that the high-risk individuals had lower perceived 
behavioral control over their eating and hence felt less able to 
change their dietary habits.88 Another study found that genetic 
testing increased self-confidence in the participant’s ability to lose 
weight, regardless of the actual result.89
Consumer acceptance
The utilization and advancement of nutrigenetics, and personal-
ized nutrition more broadly, is not just dependent on the strength 
of the data, elucidating mechanisms and defining the appropriate 
level of evidence required for implementation but requires public 
acceptance to facilitate uptake. Motivating individuals to change 
dietary behaviors is one of the biggest challenges for any nutri-
tional intervention.90 There must be ease of use and access, and a 
perception of benefit. Genetic testing, in general, has a unique set 
of barriers to uptake, and several of these remain in the context of 
nutrigenetics, regardless of outcomes.
Numerous studies have been conducted into the acceptance 
of genetic testing in general.91–95 Whilst testing is well accepted 
and becoming routine in the cases of high penetrance single poly-
morphisms, such as the BRCA1 gene in breast cancer risk, in nu-
trigenetics, however, the associations are often weaker and less 
clear.92,95 Although, attitudes vary by demographics and results 
have been mixed. It has been reported that men are more will-
ing to undergo genetic testing,96,97 but the opposite association has 
also been reported.98 It has also reported that age is a factor in 
acceptance of genetic testing; yet, some studies have found that 
older people are more willing,97,98 while others have reported that 
younger adults are the most likely to take part.96
Health has been identified as a primary motivator for undergo-
ing genetic testing,96,98 which may facilitate the uptake of nutrige-
netics, given that diet is a major modifiable determinant of disease. 
Acceptance may also be linked to current health; for example, re-
spondents with high blood cholesterol or central adiposity were 
more likely to identify as willing than those without to undergo 
genetic testing, in general, and specifically for dietary modifica-
tion.98 However, several possible outcomes to this are possible. 
Joost et al.99 suggested that individuals identified as having a 
higher disease risk through genetic testing may be more motivated 
to comply with a dietary intervention; however, it was also noted 
that knowledge of a genetic predisposition may result in a fatalis-
tic attitude and reduced compliance. Furthermore, Hunter et al.100 
reasoned that a negative result may lead to reduced motivation as 
individuals become reassured that they will not develop disease. 
Communicating the nuanced nature of risk and risk modification 
through nutrigenetics will be vital to ensure responses to informa-
tion are not detrimental to outcomes.
Interestingly, in a study of familial hypercholesterolemia, par-
ticipants with the at-risk polymorphisms were less likely to believe 
that eating a lower fat diet would reduce their cholesterol levels, 
and more likely to believe that medication would.101 Acceptance of 
genetic testing and personalized nutrition may not depend on the 
actual science but on the consumers’ understanding of its implica-
tions for their personal health. However, following a systematic re-
view, Marteau et al.101 argued in addition to significant gaps in the 
relevant science, there is limited evidence that nutrigenetic dietary 
advice will motivate appropriate behavior changes.
Technology and regulation
Web-based and smartphone technologies increase product reach 
and ease of delivery, but also raise issues of data security and accu-
racy of information. However, the technology for offering direct-
to-consumer genetic testing has out-paced regulation for its provi-
sion, at times out-pacing the scientific evidence. Therefore, there 
needs to be a progression of regulation and technology to ensure 
consumer privacy is protected, data is appropriately stored, and 
that consumers are not misled. Early practitioners of nutrigenetics 
need to be mindful that inaccurate information offered prematurely 
can damage the reputation of the field. This may be exacerbated 
by the delivery of genetic information outside of a clinical setting.
Several studies have documented concerns regarding the tech-
nology used to provide nutrigenetic information. These include on-
line privacy concerns, and the potential for information to be mis-
used by insurers, employers, governments or other entities for profit 
or exploitation.102–104 Advances in technology have driven the rise 
of personalized nutrition in general and nutrigenetics specifically. 
This includes the advances in genetic testing technology and the 
reduction in cost, as well as the use of technology for the collection 
and dissemination of information. The expansion of internet deliv-
ery systems needs to be considered in personalized nutrition. As 
oversight and regulation varies by jurisdiction, it is reasonable for 
consumers to be cautious about their privacy and future use of their 
data. Additionally, provision of results directly to the consumer 
may be harmful without the input of a genetic counselor.105
Ethical considerations for implementation
There is significant debate surrounding whether or not the current 
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knowledge base is sufficient for ethically responsible implementa-
tion of nutrigenetic testing.23,25,106,107 While there is still much to be 
discovered, we need to consider if we are holding nutrigenetics to 
a higher standard than generic population recommendations.23 The 
ethics of implementation may need to be considered on a case-by-
case basis. For some gene-nutrient interactions, there is significant 
evidence that for some individuals with particular genotypes there 
could be a benefit from following dietary patterns other than those 
recommended by the standard guidelines; however the strength of 
evidence varies depending on the association in question. The key 
question is how to proceed in the face of uncertainty. Gorman et 
al.23 argue that a precautionary approach should be adopted, sug-
gesting that personalized dietary advice should be offered only in 
cases where there is strong scientific evidence for health benefits, 
followed by continued stepwise evaluation to identify unforeseen 
behavioral and psychological effects.23
Future research predictions
The use of genotypic information in personalized nutrition offers 
considerable future promise, but significant barriers exist to suc-
cessful implementation, independent of scientific knowledge. These 
include consumer acceptance, ethical, technological and regulatory 
considerations. Research into nutrigenetics has produced inconsist-
ent results; however, the same could be said for conventional nutri-
tion studies. This is not necessarily due to the overall quality of the 
research and the magnitude of the body of knowledge, rather it is 
due to the complexity interactions between nutrition, genetics, and 
long-term health. Improved frameworks are required to translate 
nutrigenetic studies into usable guidelines to direct practicing nutri-
tion and medical professionals. This will require an interdiscipli-
nary approach, including geneticists, bioinformaticians, nutrition-
ists, dietitians and other biomedical professionals.108
Furthermore, additional research is needed not only into the 
gene-nutrient interactions themselves but also into the public atti-
tudes and acceptance on nutrigenetics and the associated risks and 
benefits of uptake. Without a holistic approach to implementation, 
it is unlikely that nutrigenetics will deliver on its early promise to 
improve health outcomes.
Conclusions
The ongoing reduction in costs of genetic testing, and the im-
proved technology available to collect and disseminate informa-
tion will lead to ongoing improvements in both quality and quan-
tity of relevant data. There is significant evidence of gene-nutrient 
interactions in a number of chronic conditions, such as cardiovas-
cular disease, diabetes and obesity, and nutrigenetics could lead to 
improved outcomes for patients and consumers. However, imple-
mentation of nutrigenetic testing in the mainstream will depend on 
numerous factors, including regulation, technology and consumer 
acceptance, and not just availability of scientific evidence. It is also 
necessary for the public and implementing authorities to decide 
what level of evidence is required before nutrigenetics is no longer 
considered to be controversial.
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